Johns Hopkins Innovations

Johns Hopkins Medicine

Innovations in Cardiac Imaging

“New Windows to the Heart”

M ay, 19th 2011

Aris Melissaratos - Senior Advisor to the President - [email protected] – 410-516-6511

Wesley D. Blakeslee, J.D. - Executive Director – [email protected] - 410-516-8300

R. Keith Baker, Ph.D., M.B.A. - Senior Director, Technology Licensing – [email protected] - 410-516-4563

Glen Steinbach – Senior Director, Finance / Administration - [email protected] – 410-516-4963

R. Keith Baker, Ph.D., M.B.A.Senior Director, Technology Licensing

Sigrid M. Volko, Ph.D.Senior Licensing Associate

Daniel Potvin, Ph.D.Licensing Associate

Nakisha D. M. Holder, Ph.D.Technology Analyst

Oncology PharmacologyOtolaryngologyChemistryDermatologyMolecular & Comparative MedicineBiological ChemistryBiology Molecular Biology & GeneticsCell Biology

410-516-4563 [email protected]@[email protected]@jhu.edu

Heather A. Bakalyar, Ph.D., M.B.A.Portfolio Director

Pauline A. Callinan, Ph.D.Licensing Associate

Laura Mitchell, Ph.D.Licensing Associate

Aditi Martin, Ph.D. Technology Analyst

MedicineNeurosciences / Neurosurgery / Neurology Psychiatry and Behavioral SciencesInstitute for Basic Biomedical Sciences (Centers)Anesthesiology & Critical Care MedicineKennedy Krieger InstitutePediatricsBiomedical Engineering

[email protected]@[email protected]@jhmi.edu

Andrea E. Doering, Ph.D., M.B.A.Portfolio Director

Rachel A. Cassidy, Ph.D., M.B.A.Associate Director

Jeffrey James Licensing AssociateAlevtina G. Zhelonkina, Ph.D.

Technology Analyst

PathologyOphthalmology Bloomberg School of Public HealthUrologyPhysiologyOb / GynBiophysics & Biophysical ChemistryChemical & Biomolecular Engineering


Eugene Yelden, Ph.D., M.B.A.Interim Portfolio Director

Ami D. Gadhia, J.D., LL.M.Licensing Associate

Taylor L. Jordan, J.D. Licensing AssociateNestor E. Francoleon, Ph.D. Technology Analyst

RadiologyPhysical Medicine and RehabilitationOrthopedic SurgeryPaul H. Nitze – Carey Business SchoolSchool of Advanced International StudiesEngineeringPhysics and Astronomy (A&S)SurgeryWilmer Eye Institute


www.scienceparkjohnshopkins.netA development of Forest City - New East Baltimore Partnership

DOWNTOWN BALTIMORE

SCIENCE + TECHNOLOGY PARK AT JOHNS HOPKINS

JOHNS HOPKINS MEDICAL CAMPUS

Bring your company to the Science + Technology Park at Johns Hopkins and join a community of science working to translate scientific discoveries into medical solutions.

Where science and business grow.

Iatrica

Cureveda

Organized by:

May 19, 2011

Baltimore, MD

Johns Hopkins Technology TransferJohns Hopkins Technology Transfer (JHTT) advances JHU’s mission to bring the benefits of discovery to the world. We do this by supporting JHU faculty entrepreneurship, fostering university-industrial relationships, and by moving university inventions into the marketplace where they can be developed into useful products for the public good. We engage strategically with faculty, industry, sister institutions and funding entities as a vital component of the University’s commitment to social responsibility and public service, and to disseminate the benefits of research.

Hopkins Innovations2011

“The Promise of Medice-The Promise of Innovation”

Contacts:

Helen Montag 410-371-8776 Elizabeth Good 443-253-5857Dana Weisgerber 443-610-8535

8:00am-9:00am Exhibitors Set-up

9:00am-10:00am Registration, Coffee and Exhibition

10:00am-10:30am Opening and Welcome by Edward D. Miller, MD Frances Watt Baker and Lenox D. Baker Jr.

Dean of the School of Medicine

Chief Executive Officer, Johns Hopkins Medicine

Cardiac Imaging @ Hopkins: The State and Future of Cardiovascular Imaging Gordon F. Tomaselli, MD Chief of Cardiology, Michel Mirowski, MD Professor of Cardiology

Johns Hopkins Medicine

10:30am-12:00pm ADVANCING IMAGING APPLICATIONS TO IMPROVE THERAPEUTIC OUTCOMES

MODERATORS: GORDON F. TOMASELLI MD SAMUEL A. WICKLINE MD

PANELISTS: “Using Imaging to Predict Cardiovascular Events and Assess the Impact of Therapeutic Interventions”- ROBERT WEISS, MD

“The Future of Image Guided Intervention”- HENRY HALPERIN, MD, MA, FAHA

“Cardiovascular Image Informatics and Computing” - RAIMOND L. WINSLOW,PHD

“Advances in Noninvasive Imaging: From Patients to Populations”- DAVID A BLUEMKE, MD, PHD

12:00pm-1:30pm LUNCH & KEYNOTE by SAMUEL A. WICKLINE, MD

“Translational potential for multimodal cardiovascular imaging with targeted nanostructures”

AGENDA




















Technology Analyst








1:30pm -3:30pm COMMERCIALIZING CARDIAC IMAGING: TRANSITIONING FROM THE UNIVERSITY TO THE MARKETPLACE

MODERATORS: WESLEY D. BLAKESLEE, JD ELLIOT R. MCVEIGH, PHD

PANELISTS:

“A Sharper Image: Unmet Needs & Unbearable Costs”- JOSEPH M. SMITH, MD, PHD, FACC:

“From Idea to Commercialization in the Academic Hospital Setting: Challenges for the Future of Medicine”-RAFAEL BEYAR, MD, DSC, MPH

“Balancing Regulation and Innovation: FDA Center for Devices and Radiological Health Perspective”- BRAM D. ZUCKERMAN, MD

“First in Man Studies – How Do We Get There?”- OWEN FARIS, PHD

3:30pm-4:00pm Coffee Break & Exhibition

4:00pm-5:30pm INDUSTRY/HOPKINS IMAGING PARTNERSHIPS: CASE STUDIES

MODERATORS: JONATHAN S. LEWIN, MD

PANELISTS:

CHRISTINE H. LORENZ, PHD

WARD M. HAMILTON

JOEL BECKER

“Hopkins and Toshiba- The CORE of a Partnership”- RICHARD MATHER, PHD

5:30 pm-5:45 pm Closing and parting thoughts by MICHAEL S. ROSEN

5:45pm-7:30pm Coktail Reception

AGENDA




















Technology Analyst








SENIOR MANAGEMENT

LICENSING GROUPS

100 North Charles Street, Suite 500, Baltimore, Maryland 21201

Phone: (410)5 16-8300 / Main Fax: (410) 516-4411MTA Fax: (410) 516-6499 /

IP Fax: (410) 516-5113 /

Finance Fax: (410) 516-0252

Email: [email protected] JHTT Website: http://www.techtransfer.jhu.edu

MATERIAL TRANSFER AGREEMENTS

AFFILIATES

CORPORATE RELATIONS, VENTURES, SALES & MARKETING

Peter Ball, J.D - Transactional Agreements Manager [email protected] 410-516-6055Ryan M. Vinton, M.S. – Licensing Associate [email protected] 410-516-6674Matthew Hartman, B.A. – Licensing Associate [email protected] 410-516-3979

Helen MontagDirector, Corporate Relations [email protected] 410-516-4976

Elizabeth GoodDirector, Ventures [email protected] 410-516-4408

Montserrat Capdevila Director, Sales, Marketing and International Relations [email protected] 410-516-6654

Aditya Polsani,B .D.S., M.S.Industrial Liaison Associate

Biomedical EngineeringBrain ScienceI nstitute

[email protected]

John N. FiniDirector, Homewood Intellectual Property & TechnologyBenjamin Gibbs, B.A. Technology Commercialization Representative

Whiting School of EngineeringKrieger School of Arts & Science

[email protected]@jhu.edu

Joynita SurTechnology Analyst

[email protected]

Questions? [email protected]

www.techtransfer.jhu.edu

CancerCleanTechImmunologyInfectious DiseasesInformation TechnologyMaterial SciencesMetabolic DisordersNanobiotechnologyNeurology & NeurosciencesOphthalmologyOrganic ElectronicsPharmacogenomicsPhysics of CancerRegenerative MedicineRoboticsStem Cell Technologies

Diagnostics » Assay Methodologies » Companion Diagnostics » Biomarkers

Engineering » Industrial Machinery » BioMEMS

Environment » Biofuels » Bioremediation

Healthcare » Software

» Devices

Imaging » Ultrasound » CT & X-Ray » Nuclear Medicine

100 N. CHARLES ST. 5TH FL. BALTIMORE MD 21201 P : 410.516.8300 F : 410.516.4411

Informatics » Bioinformatics

» Algorithms

Medical Devices » Biomaterials

» Drug Delivery

» Surgical Devices

Research Tools » Animal Models

» Antibodies

» Cell Lines

» Drug Screening

Therapeutics » Biologics

» Nucleic Acid Therapies

» Small Molecules

» Vaccines

by science area

Now Available!

LICENSING / S TART-UP OPPORTUNITIES by application area

Technology Commercialization

Start-Up Ventures

Material Transfers

Sponsored Research

Core Facilities

Research Parks

Connect with the JHTT Community JHTT app




















Technology Analyst








Speakers

Chief Executive Officer & Director GeneralRAMBAM Health Care Campus

Gotlieb Professor of Biomedical Engineering & Medicine Technion

Rafael BeyaR , MD, DSC, MPH

SHORT BIOProfessor Rafael (Rafi) Beyar, born in Tel Aviv in 1952, graduated from the School of Medicine of Tel Aviv University in 1977 (MD), the Faculty of Biomedical Engineering at Technion in 1983 (DSc) and the Bloomberg School of Public Health, Johns Hopkins University in 2008 (MPH). In 1983, he founded the Heart System Research Center at Technion where he served as Coordinator and Director. He completed his residency in medicine at Rambam (1983-1985) and a fellowship in cardiology at Johns Hopkins University (1985-1987). He was appointed Professor of Biomedical Engineering and Medicine at Technion in 1996 and served as Director of the Division of Invasive Cardiology at Rambam. He served as Visiting Professor at Johns Hopkins University for several years. In 1998, he was elected as Dean of the Rappaport Faculty of Medicine at Technion and served for the full term. Under his leadership, Professor Avram Hershko and Professor Aaron Ciechanover, members of the Rappaport faculty of medicine at Technion were awarded the Nobel Prize in Chemistry in October 2004.

Professor Beyar has received prestigious prizes over the course of his career, among them the Taub Prize for excellence in Research in 1999 and the Michelle Mirowski Award for Accomplishments in Cardiovascular Medicine, Israeli Heart Association in 2002. In 2005 he was nominated to the prestigious Johns Hopkins Society of Scholars for his worldwide contribution to cardiovascular science and for establishing the Technion-Johns Hopkins Collaboration Program on Biomedical Sciences and Engineering.

Beyar’s research and clinical interests range from mathematical simulation to imaging and analysis of the cardiovascular system, as well as the development of stents and new technology in cardiology. He has authored over 150 scientific publications and 11 books, is founding editor of Acute Cardiac Care Journal, endorsed by the European Society of Cardiology and is organizer and founder of leading professional cardiovascular meetings.

Since February 2006, Beyar has been serving as General Director of the Rambam Health Care Campus in Haifa, Israel, which is the major academic hospital serving Northern Israel. In the summer of 2006, he led the hospital through the second Lebanon war when Rambam was treating patients under fire. Beyar is now spearheading a major development plan in both clinical and research facilities at Rambam, focusing on the combination of medicine science and technology that will most benefit patients’ health care.

Executive DirectorJohns Hopkins Technology Transfer

WeSley D. BlakeSlee , JD

SHORT BIOWesley Blakeslee is Executive Director of Johns Hopkins Technology Transfer. He was formerly an Associate General Counsel at The Johns Hopkins University where he practiced intellectual property and complex business law. Wes holds an Engineering Degree (with Honors) from Penn State University, and a law Degree (Order of the Coif), from the University of Maryland School of Law and is a Certified Licensing Professional. Wes began his professional career as an engineer and systems analyst with the National Aeronautics and Space Administration, where, among other things, he designed and wrote real time operating systems for spacecraft testing and post-launch control, and managed a programming group. After Law School, Wes entered private practice, was a partner in a small regional firm, and in 1983 Wes formed his own practice in Westminster, Maryland, USA.

From 1983 to 1989, while in private practice, Wes also served as Director of Computer Development at the University of Maryland Law School, where he also taught Computer Law. In February 1999, Wes became Associate General Counsel at The Johns Hopkins University. Wes also served for many years as a Director of a National bank. Wes is frequently a featured speaker at national, state and local conferences, and on behalf of bar associations and numerous conference organizations. Wes has been cited as a national authority on intellectual property issues in the Chronicle of Higher Education, and other publications.

Notes

Director, Radiology and Imaging Sciences National Institutes of Health/Clinical Center

DaviD a BlueMke, MD, PHD, MSB

SHORT BIODavid A Bluemke, MD, PhD, MsB is the Director of Radiology and Imaging Sciences, National Institutes of Health Clinical Center, in Bethesda Maryland. He is a Senior Investigator at the National Institute of Biomedical Imaging and Bioengineering and adjunct Professor of Radiology and Medicine at the Johns Hopkins University School of Medicine. Dr. Bluemke, an American Heart Association and American College of Radiology fellow, conducts imaging research on cardiovascular disease and its complications and seeks to better understand how subclinical disease can be detected with newly developed imaging technologies, described, and tracked over time. Dr. Bluemke has authored more than 350 peer-reviewed publications and 27 book chapters and monographs. He earned his medical degree at the University of Chicago’s Pritzker School of Medicine, his PhD from the University of Chicago’s Department of Biophysics and Theoretical Biology and his Masters in business from Johns Hopkins University.

Director, Radiology and Imaging Sciences National Institutes of Health/ Clinical Center

OWen faRiS, PHD

SHORT BIOOwen Faris received his PhD in biomedical engineering from Johns Hopkins University in 2003. Since that time he has worked within the Division of Cardiovascular Devices at the FDA, first as a scientific reviewer and currently as the Acting Deputy Director. Dr. Faris’ research and review background in the areas of electrophysiology device technologies as well as magnetic resonance imaging has made him an agency expert in MRI compatibility issues for active implantable medical devices.

Dr. Halperin received a B.S degree in physics with highest distinction from Purdue University in 1971, and received an M.A. degree in physics from the University of California, Berkeley in 1972. He received an M.D. degree from Louisiana State University, New Orleans in 1977. He was a fellow in cardiology at The Johns Hopkins Hospital 1981-84. He is a member of Phi Beta Kappa, an Established Investigator and Fellow of the American Heart Association, a Fellow of the Heart Rhythm Society, a McClure Fellow of the Johns Hopkins University Applied Physics laboratory, and an Eagle Scout. He is the co-director of the Johns Hopkins Cardiovascular Imaging Center, and director of Advanced Cardiovascular Life Support at Johns Hopkins Hospital. He is a past chair of the AHA Advanced Cardiovascular Life Support Subcommittee and a past member of the Emergency Cardiac Care Committee.

Dr. Halperin has done extensive research in CPR. In studies that included computer modeling and advanced imaging, he investigated hemodynamic and airway mechanisms operative during CPR. These findings were instrumental in developing AHA recommendations for optimizing the chest compression rate and depth during CPR. In addition, these studies clarified the contribution of airway collapse, air-flow and air?trapping to generation of intrathoracic pressure during chest compression. He also did studies showing that improving blood flow during CPR could increase survival. He then developed methods and devices, most of which are clinically available, for monitoring and improving chest compression, while avoiding interruptions in chest compression. He developed (1) an accelerometer-based chest-displacement-measuring technology enabling real-time feedback on the quality of chest compression and its effect on outcomes, (2) a system for markedly reducing the chest-compression-induced artifact in the ECG, allowing correct interpretation of the ECG without interrupting chest compression, and (3) automatic mechanical chest-compression devices for improving blood flow.

Dr. Halperin has also done extensive research in electrophysiology. He invented ways of combining the anatomic information from real-time magnetic resonance imaging (MRI), with catheter ablation, to determine, through direct visualization, if complete ablations are present; and if not, to complete such ablations. He is one of the key pioneers studying interactions between MRI and cardiac rhythm devices. MRI is generally denied to patients with implanted devices, due to potential safety concerns. He showed, however, that modern devices can be MRI safe, because of improved technology. The clinical utility is substantial since more than 90 percent of diagnostic questions are answered with MRI, compared with only 20 percent with conventional imaging. Other centers are using these data to start their imaging programs, and the algorithm for safe MRI scanning has been adopted by the AHA. Dr. Halperin also introduced MRI in the study of mechanisms of arrhythmias, and this approach has been adopted by many research groups. Among other findings, he showed that a major substrate for ventricular tachycardia is scar, sometimes mixed with normal tissue, which can be imaged with MRI, and which are ideal targets for ablation.

Ten of his students have received young investigator awards from the American Heart Association and Heart Rhythm Society, and he has had continuous support from the National Institutes of Health for his research programs. He has more than 130 peer-reviewed publications and more than 25 patents issued.

Professor of Medicine Biomedical Engineering and RadiologyDirector Johns Hopkins Hospital Advanced Cardiac Life Support TrainingDirector Cardiology Bioengineering Laboratory Johns Hopkins Medicine

HenRy HalPeRin, MD, Ma, faHa, fHRS

SHORT BIO

Senior Vice President, Marketing, St. Jude Medical Cardiac Surgery

JOel BeCkeR

SHORT BIOJoel Becker became Senior Vice President, Marketing for the St. Jude Medical United States Sales Division in February 2011. Mr. Becker leads the overall marketing efforts, and assumes responsibility for overseeing product marketing, clinical education and training, marketing communications and fellows programs.

Mr. Becker first joined St. Jude Medical in 1993 as a Senior Associate in Corporate Development. He also previously held the position of Marketing Manager and European Regional Sales Director within the Cardiac Surgery Division. In 1999, Mr. Becker left the company to join Myocor, Inc., as Senior Vice President of Marketing and Business Development. Mr. Becker rejoined St. Jude Medical’s Cardiac Surgery Division in 2002, working in marketing and was named Vice President of Marketing and Business Development 2003.

In 2004, Mr. Becker became a founding member of the management team for the St. Jude Medical Atrial Fibrillation Division, and was named Vice President of Marketing and Business Development. He later transitioned to Vice President, Business and Program Development, overseeing program management, clinical affairs and business development.

Notes

Dr. Lewin is the Martin Donner Professor and Chairman of the Russell H. Morgan Department of Radiology and Radiological Science at Johns Hopkins University, and the Radiologist-in-Chief at Johns Hopkins Hospital, with secondary appointments as Professor of Oncology, Neurosurgery, and Biomedical Engineering. Dr. Lewin received his undergraduate degree in Chemistry from Brown University in 1981 and his Doctor of Medicine from Yale University in 1985. Following his internship at Yale-New Haven Hospital and residency in Diagnostic Radiology at University Hospitals of Cleveland, he completed a Magnetic Resonance Research Fellowship in Germany, a Neuroradiology fellowship at the Cleveland Clinic, and additional training in Head and Neck Radiology at the Pittsburgh Eye and Ear Hospital.

Prior to his current position, he was the Director of the Division of Magnetic Resonance Imaging at the University Hospitals of Cleveland, and was Vice Chairman for Research and Academic Affairs in the Department of Radiology at Case Western Reserve University. He has been a pioneer in interventional and intra-operative MR imaging, and has published approximately 175 peer-reviewed manuscripts and over 50 chapters, reviews, and other invited papers on topics including the basic science and clinical aspects of interventional MR imaging, functional MR imaging, head and neck imaging, MR angiography, small animal imaging, and the imaging of acute stroke. Dr. Lewin has been PI and Co-PI on NIH and other Federal and State grants with awards of over $10 million in direct costs, as well as a Co-investigator on a number of other grants and projects. He is a Fellow of the International Society for Magnetic Resonance in Medicine and of the American College of Radiology and has given over 130 invited lectures on a number of topics in Magnetic Resonance Imaging. He has served on numerous national committees, editorial boards, and grant review groups for foundations and the NIH, and on the Task force on minimally-invasive cancer therapy for the National Cancer Institute. Currently, he is on the Board of Chancellors of the American College of Radiology and serves on the Board of Directors or Executive Committees and/or as an Executive Officer for the American Roentgen Ray Society, Association of University Radiologists, Society of Chairs of Academic Radiology Departments, Academy of Radiology Research, and the International Society for Strategic Studies in Radiology.

Martin Donner Professor and Chairman of the Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University Radiologist-in-Chief Johns Hopkins Hospital

JOnatHan S. leWin, MD, faCR

SHORT BIO

Director of the Center for Applied Medical Imaging Siemens Corporate Research

CHRiStine H. lORenz, PHD

SHORT BIODr. Christine Lorenz serves as Director of the Center for Applied Medical Imaging at Siemens Corporate Research (SCR), a collaboration with Siemens Healthcare, based in Baltimore, Maryland, USA, and also as Competence Group Manager at SCR in Princeton, NJ, focusing on people development and responsible for a multicultural team of over 130 scientists and engineers. Dr. Lorenz received her PhD in biomedical engineering and held several faculty positions in academic radiology, cardiology, and biomedical engineering with research focused on cardiovascular MRI prior to joining Siemens. She joined Siemens Medical Solutions in the United Kingdom in 2000 as a Senior Scientist, and has since held several R&D management positions with Siemens Healthcare in Germany and Siemens Corporate Research in the USA. Her research is focused on developing procedures for image-guided minimally invasive procedures, with emphasis on MRI, and her group collaborates with a wide variety of academic and industrial partners in this field. Her group is also responsible for managing research relationships with a number of institutions in the area of MRI, with a focus on translating research results into improved products for Siemens.

Senior Vice PresidentZOLL Medical Corporation

WaRD M. HaMiltOn

SHORT BIOWard M. Hamilton is Senior Vice President and Vice President of Marketing at ZOLL Medical Corporation. Prior to joining the Company in 1992, Mr. Hamilton previously held positions as Director of New Business Development and Director of Marketing for ACLS products for Laerdal Medical Corporation, as a Marketing Manager for Datascope Corporation, and with the City of Pasadena, California, as a firefighter and paramedic. He taught health and bioscience at Pasadena City College and has a B.A. in political science from Hartwick College and a M.P.A. from the University of Southern California. He has worked in the field of emergency care and resuscitation for more than thirty years.

Massey Professor and DirectorDepartment of Biomedical Engineering

elliOt R. MCveigH , PHD

SHORT BIODr. McVeigh received his undergraduate degree in Physics, and his PhD in Medical Biophysics, both from the University of Toronto. In 1988 Dr. McVeigh joined the Radiology Faculty at Johns Hopkins, establishing a research program in cardiac MRI with Elias Zerhouni. In 1991 Dr. McVeigh founded the Medical Imaging Laboratory in the Department of Biomedical Engineering as part of a Whitaker Development Award. Over the next nine years many graduate students in the Medical Imaging Laboratory received training in translational research in imaging sciences working with teams that included clinical scientists from Hopkins Medicine. In 1999, Dr McVeigh moved to the intramural research program at the NIH to found a research laboratory developing cardiovascular interventional MRI. Working with clinical colleagues Dr. McVeigh’s laboratory has demonstrated numerous novel applications, three of which are: the first MRI guided injections of therapeutic agents directly into the myocardium, the first simultaneous electrical and mechanical measurements of cardiac function with MR, the first MR guided aortic valve replacement in the beating heart. In 2007 Dr. McVeigh was appointed Massey Professor and Director of the Department of Biomedical Engineering.

Notes

DR. EDWARD MILLER was named chief executive officer of Johns Hopkins Medicine, the 13th dean of The Johns Hopkins University School of Medicine in January 1997. As CEO, Dr. Miller is responsible for both the school and the health system and reports directly to the university president and the chairman of the board of Johns Hopkins Medicine.

Under his aegis, both The Johns Hopkins Hospital and school of medicine continue to be ranked among the very best in the nation by U.S. News & World Report, and the school continues to rank at the top in NIH research funding. As part of Dr. Miller’s vision to improve access to Johns Hopkins Medicine through the development of a regional, integrated health care delivery system, Howard County General Hospital, strategically located between Baltimore and Washington was acquired and integrated into Johns Hopkins Medicine. Dr. Miller also led the effort to integrate Suburban Hospital and Health System into Johns Hopkins Medicine, a key partnership given the proximity of the Bethesda, MD facility to the National Institutes of Health and the Washington, D.C. metro area.

One of his most significant accomplishments as dean/CEO has been the massive rebuilding and renovation projects that have transformed the East Baltimore medical campus into a medical center where the most modern of buildings sit among the most historic. The jewel in the crown of this campus revitalization effort has been one of the largest hospital construction projects in the nation – two new state-of-the-art hospitals for adult and pediatric patients. Other important campus construction projects completed under Dr. Miller’s tenure include clinical and research buildings for the Sidney Kimmel Comprehensive Cancer Center, the Broadway Research Building, the Anne and Mike Armstrong Medical Educational Building, and the new Robert H. and Clarice Smith building that is part of the Wilmer Eye Institute.

Dr. Miller also directed the implementation of a diversity initiative that places diversity and inclusion alongside excellence, integrity and collegiality as core fundamentals within Johns Hopkins Medicine, and under his direction, a new school of medicine curriculum, Genes to Society, was developed and introduced, representing the first wholesale academic overhaul at the school in two decades. The curriculum, nearly six years in the making, centers on advances in understanding of the human genome and will feature new courses and modified existing ones.

An anesthesiologist who has authored or co-authored more than 150 scientific papers, abstracts and book chapters, Dr. Miller joined Johns Hopkins in 1994 as professor and director of the Department of Anesthesiology and Critical Care Medicine and was named interim dean of the school of medicine in 1996. He came to Hopkins after eight years at Columbia University, where he served as professor and chairman of the Department of Anesthesiology. Prior to that, he spent 11 years at the University of Virginia.

Dr. Miller is a member of the Institute of Medicine of the National Academy of Sciences and is a fellow of the Royal College of Physicians and the Royal College of Anaesthetists. He is also a member of the State of Maryland’s Health Care Access and Cost Commission and serves on the boards of the PNC Bank and CareFusion.

Frances Watt Baker and Lenox D. Baker Jr. Dean of the School of Medicine Chief Executive Officer, Johns Hopkins Medicine

eDWaRD D. MilleR , MD

SHORT BIO

Senior Manager, Clinical Programs Toshiba Medical Research Institute

RiCH MatHeR , PHD

SHORT BIOI have worked in medical imaging for the past 17 years starting with my formal training at UCLA in the Biomedical Physics graduate program. I received my PhD in 1997. Following graduation, I was a scientist and engineer for Imatron, Inc developing applications and research on the electron beam CT scanner. I spent 2 years working as a program manager in CT for GE Healthcare before joining Toshiba in 2004. At Toshiba, I have been integrally involved in research projects that validate Toshiba’s CT products in the medical community. I am also the chief Medical Physicist for Toshiba CT in the US and the resident expert on CT dosimetry for Toshiba. My research work has been published in peer reviewed journals, including Radiology, the American Journal of Radiology, Academic Radiology, and Physics in Medicine and Biology, the American Journal of Neuroradiology, and the International Journal of Cardiovascular Imaging. I have also presented my work at a number of scientific sessions, including the American College of Cardiology, the American Association of Physicists in Medicine, the RSNA, and the International Society for Magnetic Resonance in Medicine.

Notes

Senior Vice-President New Business Development Forest City Enterprises’ Science + Technology Group

MiCHael S. ROSen

SHORT BIOMichael Rosen is Senior Vice-President, New Business Development for Forest City Enterprises’ Science + Technology Group, a national real estate developer which creates and manages life science parks in the U.S. Prior to this, he was president of Rosen Bioscience Management, a company providing CEO expertise to Midwest start-up life science companies, such as Immune Cell Therapy (cancer vaccines), Renovar (renal disease diagnostics), LCR Woundcare, etc.

He is a veteran of the biotechnology and pharmaceutical industries, having spent twenty years with three major pharmaceutical companies, Pfizer, Bristol-Myers Squibb, and Monsanto/Searle, in international marketing, business development, and management roles. Additionally, he has been CEO of European and U.S. biotech companies, including PharmaMar, S.A. (oncology products); Endorex Corp. (drug delivery and cancer products company located in Chicago) which he listed on the Amex; and Barbeau Pharma ( a specialty pharma company). Mr. Rosen was a co- founder of the Illinois Biotechnology Industry Organization (“IBIO”), where he has served as Vice-Chairman, as well as a member of its board of directors since its inception.

Mr. Rosen received his B.A. in Sociology & International Relations from Beloit College, and his M.B.A. in International Business from the University of Miami. Mr. Rosen serves as a member of Northwestern University’s Industry Advisory Board for its Masters of Biotechnology program and a member of the board of the America-Israel Chamber of Commerce –Chicago. He is the biotech columnist for ePrairie.com and the Wisconsin Technology Network News. Mr. Rosen is also a professor of International Management and International Marketing at the Lake Forest Graduate School of Management MBA program. Mr. Rosen has lived in Japan, the U.K., Italy, Spain, Colombia, Chile, Guatemala, Peru, and Costa Rica, and worked in Europe, Latin American, Canada and Asia.

Chief Medical and Science OfficerWest Wireless Health Institute

JOe SMitH, MD, PHD

SHORT BIODr. Joseph Smith is Senior VP and Chief Medical Officer of Guidant CRM. Before joining Guidant, Dr. Smith was director of the Arrhythmia Institute and research director of the Cardiovascular Group, both in Fairfax, VA. Dr. Smith served for more than seven years on the Guidant - CRM Medical Advisory Board before assuming his current role.

Dr. Smith holds an undergraduate degree in Electrical Engineering (EE) from Johns Hopkins University, a Master’s degree in EE from the Massachusetts Institute of Technology (MIT), a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Division of Health Sciences and Technology, and an MD from Harvard Medical School. He completed his medical internship and residency at Brigham and Women’s Hospital in Boston, and completed his cardiology and clinical electrophysiology training at Brigham and Women’s hospital, the Krannert Institute of Cardiology in Indianapolis, and Washington University in St. Louis. He has held academic positions at the School of Medicine and the Department of Biomedical Engineering at Washington University in St. Louis.

Notes

Chief of Cardiology, Michel Mirowski, MD Professor of Cardiology Johns Hopkins Medicine

gORDOn tOMaSelli , MD

SHORT BIODr. Tomaselli is a Professor of Medicine in the Division of Cardiology & Molecular Medicine at the Johns Hopkins University School of Medicine. In this role he attends the clinical electrophysiology laboratory, teaches physiology, pathophysiology, and molecular medicine to first and second year medical students, and has an active basic laboratory research program. Dr. Tomaselli is known for his work on cardiac electrophysiology and arrhythmias, and his laboratory interests include the structure and function of ion channel genes and proteins, and molecular genetic changes in excitability molecules which occur in the human heart failure.

Dr. Tomaselli is leading the clinical research efforts within the Donald W. Reynolds Cardiovascular Clinical Research Center as Co-Director. In addition to this role, he serves as the principal investigator on Project 3: Expression Profiling and Proteomic Biomarkers of Sudden Cardiac Death.

He is board certified in cardiovascular diseases, and clinical electrophysiology and pacing. He is the President of the Cardiac Electrophysiology Society, a member of the Committee on Scientific Sessions Resource Planning (CSSP) of the American Heart Association and a member of the leadership Committee for the Council on Basic Cardiovascular Sciences of the American Heart Association. He is Chairman of the Basic Sciences subsection of the NASPE – Heart Rhythm Society Program Committee. He serves on the editorial board of Circulation and is an Associate Editor of Circulation Research and is a former permanent member and now on reviewer reserve of the Electrical Signaling, Ion Transport and Arrhythmias [ESTA] Institutional Review Group at the National Institutes of Health, The National Heart Lung & Blood Institute.

Clarence Doodeman Professor of Cardiology Johns Hopkins Medicine

ROBeRt WeiSS, MD

SHORT BIODr. Robert G. Weiss is a Professor of Medicine with a joint appointment in Radiology at the Johns Hopkins School of Medicine. He has a long scientific interest in myocardial metabolism and is on the forefront of developing and implementing imaging technology to help clinicians better understand cardiovascular disease and correctly diagnose its presence in people.

Dr. Weiss graduated from Dickinson College with a summa cum laude degree in Physics and later graduated from Milton S. Hershey School of Medicine of the Pennsylvania State University. He completed a residency on the Osler Medical Housestaff and a fellowship in cardiovascular medicine at Johns Hopkins while spending time at the National Institute of Aging, NIH. He has been on the full-time faculty at Johns Hopkins since 1989 and is a former Established Investigator of the American Heart Association and Director of the DW Reynolds Clinical Cardiovascular Center at Johns Hopkins.

With a broad spectrum of clinical and basic research interests in cardiovascular medicine and imaging, Dr. Weiss has a strong track record of innovation and leadership at Johns Hopkins University. Notes

Professor of Medicine, Physics, Biomedical Engineering, Cell Biology and Physiology;

Director, Washington University Consortium for Transla-tional Research in Advanced Imaging and Nanomedicine (C-TRAIN);

Director, Siteman Center For Cancer Nanotechnology Ex-cellence; Executive Faculty, Institute of Biological and Med-ical Engineering;

Co-Director of Cardiovascular Engineering Graduate Train-ing Program, Biomedical Engineering Department, Washington University School of Medicine, St. Louis, MO

SaMuel a. WiCkline, MD

SHORT BIOMy research lab has focused on topics related to nanomedicine for cancer and cardiovascular applications since 1995. Cross disciplinary nanomedicine research is conducted with many collaborators in Physics, Engineering, Mathematics, Cellular Biology, Radiology, Oncology, Biophysics, Surgery, and Pathology/Immunology among others. The laboratory is purposely translational and more than 50 issued or pending US patents, 2 new biotech startups (nanomedicines, and semiconductor nanodevices for imaging), and multiple licensing arrangements for technology invented in the lab have resulted.

The current application seeks to continue translational work in the targeted delivery of peptide toxin therapeutics for cancer. Specifically, melittin, a pore forming peptide component of bee venom, is a potent anticancer agent, but never has been delivered safely in sufficient quantities in vivo to affect cancer growth. We have developed a number of useful colloidal carriers for nanomedicine imaging (multimodal) and drug delivery applications and one in particular exhibits great promise for delivery of this agent that otherwise destroys conventional vehicles such as liposomes. The proposal seeks to bridge the well known translational gap between academic discovery and commercial adoption for preclinical development by performing the necessary proof of concept studies ion a realistic human in mouse model of “triple negative” breast cancers, which is unresponsive to conventional therapies in recurrence. If the planned studies indicate activity in these resistant cell types that isolated from actual patients who have failed all conventional therapy, an excellent case can then be made for moving the technology into clinical development with existing partners.

SHORT BIO

Academic Appointments

2006: Director, Consortium for Translational Research in Advanced Imaging and Nanomedicine (C-TRAIN), Washington University;

2006: Director, Siteman Center for Cancer Nanotechnology Excellence, Washington University;

2009: Director, St Louis Institute of Nanomedicine

Honors

1) Alpha Omega Alpha, 1979;

2) Knowlton “Incentive For Excellence” Award, Washington University School of Medicine, 1986;

3) Clinician-Scientist Award, American Heart Association, 1988-93;

4) Established Investigator Award, American Heart Association 1993-98;

5) Member, American Society of Clinical Investigation (Elected May 1995);

6) Board of Directors, Society for Cardiovascular Magnetic Resonance (2000-2004);

7) Executive Committee for NHLBI Strategic Planning (2006-7);

8) NIH Roadmap Planning Consultant (2006); 9) NIH CMIP study section (2010-2014)

Notes

The Raj and Neera Singh Professor of Biomedical Engineering, Director, Institute for Computational Medicine, Johns Hopkins University

RaiMOnD l. WinSlOW, PHD

SHORT BIODr. Winslow is the Raj and Neera Singh Professor of Biomedical Engineering, and Director of the Institute for Computational Medicine. His research has focused on the use of computational modeling to understand the processes of excitation contraction coupling, mitochondrial energy production, and signal transduction in ventricular myocytes. He has also developed computational models of the molecular basis of arrhythmia in heart failure – work that has provided fundamental insights into possible mechanisms of sudden cardiac death in this disease. More recently, he has initiated a research program in cardiovascular informatics. He is Principal Investigator of the CardioVascular Research Grid Project, an NHLBI-funded resource, with research teams at four universities, aimed at creating a national infrastructure for sharing and analysis of cardiovascular data.

Director, Division of Cardiovascular Devices US Food and Drug Administration

BRaM zuCkeRMan, MD

SHORT BIODr. Bram Zuckerman is a graduate of the Boston University Medical School. He completed post-graduate training in internal medicine at Baltimore City Hospital and cardiology at the Johns Hopkins program. Prior to joining FDA in 1992, he was involved in basic research in hemodynamics and practiced noninvasive and invasive cardiology in Denver, Colorado and Northern Virginia. He joined the FDA Divison of Cardiovascular Devices (DCD) as a Medical Officer in 1992 and has been actively involved in clinical trial design for many new cardiovascular devices. In May 2001 he was appointed a Deputy Director in DCD. He was appointed to his current position as Director of the FDA Division of Cardiovascular Devices in




















Technology Analyst








Sponsors

Platinum Sponsor

www.forestcityscience.net/hopkins

Science + Technology Park at Johns Hopkins, an integrated life science and residential campus. The first of 5 planned life science buildings, 855 N. Wolfe Street supports sophisticated requirements of early-stage to mature life science organiza-tions. Anchored by Johns Hopkins School of Medicine’s In-stitute for Basic Biomedical Sciences, Brain Science Institute, and The Bloomberg School of Public Health; as well as several life science organizations such as Siemens Medical, The Li-eber Institute for Brain Development, Howard Hughes Medi-cal Institute, Sobran, a preclinical CRO, and several Hopkins early-stage companies. The building offers 277,000 SF state-of-the-art labs next to America’s most respected medical institution.

Gold Sponsors

www.usa.siemens.com/en/about_us/research/home.htm

Siemens Corporate Research (SCR), a division of Siemens Corporation, is comprised of more than 200 of the world’s most talented scientists, engineers and technical experts from over two dozen countries. Cross-functional research teams bring together a broad range of technical and business expertise from different disciplines. For more than 30 years, we have been developing breakthroughs in science and emerging tech-nologies. Innovative research. Effective solutions. Real business results.

www.sjm.com

It is our mission to develop medical technology and services that put more control into the hands of those who treat cardiac, neurological and chronic pain patients, worldwide. We do this because we are ded-icated to advancing the practice of medicine by reducing risk wherev-er possible and contributing to successful outcomes for every patient.

Silver Sponsors

www.healthcare.philips.com/us_en

People focused, healthcare simplified.

At Philips, we try to simplify healthcare through combining our unique clinical expertise with human insights to develop innovations that ultimately help to improve the quality of people’s lives. With a growing presence in cardiology, oncology, and women’s health, we focus on the fundamental health problems with which people are confronted, such as congestive heart failure, lung and breast cancers and coronary artery disease. Our focus is to deliver value throughout the complete cycle of care: from disease prevention to screening and diagnosis through to treatment, monitoring and health management. Philips is dedicated to making an impact wherever care happens, within the hospital - critical care, emergency care and surgery - and, as importantly, in the home.

http://www.medical.toshiba.com/

We’d like to offer special thanks to our TOSHIBA colleagues for their support, especially during this trou-bling time for their country. To learn more about the humanitarian and rebuilding efforts for Japan, please visit the USAID and Japan Relief Project pages.

www.usaid.govwww.japanreliefproject.com

Since its inception in 1875, Toshiba has worked to improve the quality of life for all people. The company’s technology, from light bulbs to laptops, has delivered on this mission with medical innovations that are Made for Life — made to improve the lives of patients, clinicians and administra-tors.

This legacy is expressed best in the partnership of Toshiba’s founding companies: Tokyo Electric Company and Shibaura Engineering. These two companies’ life-saving partnership (now Toshiba) developed one of the world’s first X-ray machines in 1932 to help physicians manage a tuberculosis outbreak in Japan. Today, Toshiba’s imaging technology continues to save lives and improve health of people around the world with some of the most powerful and patient-friendly systems available.

www.zoll.com

“Advancing Resuscitation. Today”

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibril-lation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachu-setts, Pennsylvania, and Rhode Island. More than 400 direct sales and ser-vice representatives, 1,100 business partners, and 200 independent repre-sentatives serve our customers in over 140 countries around the globe.

Bronze Sponsor

www.biosensewebster.com

Biosense Webster, Inc is a worldwide leader in the science behind the diagnosis and treatment of cardiac arrhythmias with more than 1,300 professionals in 40 countries around the world. As part of the Johnson & Johnson family of companies, Biosense Webster has globally diverse employees dedicated to bringing the best healthcare options to our cus-tomers in the most ethical ways possible. BWI has renowned training and support for electrophysiologists and allied professionals, including onsite training, online courses, and education centers in Cincinnati, Ohio; Hamburg, Germany; and Shanghai, China. Biosense Webster is shap-ing the future of electrophysiology with inspired professionals using in-novative ideas to make a tangible difference in the lives of doctors and patients. Having an unparalleled commitment to scientific discovery that supports clinical trials and publishes scientific studies to advance the practice of electrophysiology and evaluate the safety and efficacy of new medical technology, Biosense Webster has gained the reputation as a worldwide leader in diagnosis and treatment of cardiac arrhythmias.

www.cardinal.com

Cardinal Health is a Fortune 17 company that improves the cost-effective-ness of healthcare. Our Nuclear Pharmacy Services business dispenses and delivers time-critical, patient-specific radiopharmaceuticals for diagnostic imaging and therapy through a nationwide network of more than 150 nuclear pharmacies. Our dedication to high quality standards and superior customer service means the right dose gets to the right patient the right time, every time. In addition to our unit-dose service, we offer innovative customer solutions for productivity, safety, compliance and education.

www.dlapiper.com

With 4,200 lawyers located in 30 countries and 76 offices throughout Asia Pacific, Europe, the Middle East and the United States, DLA Piper is posi-tioned to help companies with their legal needs anywhere in the world. Our locally and internationally trained lawyers represent more clients in a broader range of geographies and practice areas than virtually any other law firm. We are acknowledged as one of the world’s leading life sciences law firms, offering more than 200 life sciences lawyers and patent agents working together to represent companies and investors in the biotechnol-ogy, pharmaceutical and medical device fields. Our local presence and global footprint, coupled with our strong ties to the principal business, fi-nance and technology hubs worldwide, allow us to effectively counsel and represent life companies and financiers in the global marketplace.

Exhibit Sponsor

www.astrazeneca.com

AstraZeneca is a global, innovation-driven, integrated biopharmaceuti-cal company. We discover, develop, manufacture and market prescrip-tion medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gas-trointestinal, infection, neuroscience, and respiratory and inflammation.

www.bostonscientific.com

POWERed for GROWTH

Our strategy is to lead global markets for less-invasive medical devices by developing and marketing innovative products, services and therapies that address unmet patient needs, provide superior clinical outcomes and demonstrate proven economic value.

Partner Organizations

www.americanheart.org

Ingenia 1.5T & 3.0TNew digital broadband MRI

40% improved SNR30% improved workflowChannel independent

Please come see us in the exhibit area

www.healthcare.philips.com

SpecSpecila

Special ThanksFor Your Support

Notes

siemens.com/answers

When diseases are caught early, they make less of an impact on everyone. That’s because 80% of today’s healthcare costs go toward treating late-stage diseases, like cancer and heart disease. With Siemens advanced diagnostic technology, doctors can accurately identify these killers earlier. So patients get the treatment they need sooner. Which helps save lives and cuts costs. Somewhere in America, our team of over 60,000 employees has already answered some of the nation’s toughest questions. And we’re ready to do it again.

Siemens advanced diagnostic technology helps doctors detect disease earlier. Which helps save lives—and healthcare expenses.

©S

iem

en

s AG

, 20

10

. All R

igh

ts Re

serv

ed

.

Can we stop small cellsfrom causing big problems?

St. Jude Medical is focused on reducing risk by continuously finding ways to put more control into the hands of those who save and enhance lives.

More control.Less risk.

sjm.com

St. Jude Medicalis Proud to Support Johns Hopkins Medical

ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are trademarks and service marks of St. Jude Medical, Inc. and its related companies. ©2011 St. Jude Medical. All Rights Reserved.

Every choice matters.Every decision critical.Every move confident.

Documents

Johns Hopkins Innovations